Tuesday, November 17, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Laboratoires Pierre Fabre : FDA Fast Track designation for elticertinib in NSCLC

Money Compass by Money Compass
November 17, 2026
in PR Newswire
0
Laboratoires Pierre Fabre : FDA Fast Track designation for elticertinib in NSCLC
1
SHARES
100
VIEWS
Share on FacebookShare on Twitter

CASTRES, France, Nov. 17, 2026 /PRNewswire/ — Laboratoires Pierre Fabre announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to elticertinibi (also known as PFL-721 previously STX-721), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring EGFR exon 20 insertion mutations, whose disease has progressed on both platinum-based chemotherapy and amivantamab. 

The FDA’s fast track designation is designed to expedite the development and review of therapies to treat serious conditions with significant unmet medical needs. The designation has been granted based on nonclinical data as well as preliminary efficacy data from the ongoing Phase 1/2 clinical trial (NCT06043817). It provides Laboratoires Pierre Fabre with increased opportunities for interaction with the FDA, as well as eligibility for rolling and priority review, if relevant criteria are met. 

Related posts

MAIRE: Nextchem (MAIRE) to acquire LNG process technologies from Chart Industries for $220 million

MAIRE: Nextchem (MAIRE) to acquire LNG process technologies from Chart Industries for $220 million

November 17, 2026
Xi’an Strengthens Global Economic Ties, Expands Opportunities for Investment and Cooperation

Xi’an Strengthens Global Economic Ties, Expands Opportunities for Investment and Cooperation

November 17, 2026

Elticertinib is a highly differentiated, orally bioavailable, irreversible highly selective investigational tyrosine kinase inhibitor (“TKI”) targeting epidermal growth factor receptor (“EGFR”) and ERBB2 (HER2) Exon 20 insertion (“ex20ins”) mutations. 

NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in up to 38% of tumors, depending on geography.ii,iii,iv Of this population, up to 10% have ex20ins mutations.  

“This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our R&D capabilities in oncology. It confirms our ability to bring innovative, highly differentiated therapies from research to patients, and strengthens our ambition to become a recognized global player in precision oncology,” said Eric Ducournau, Chief Executive Officer of Laboratoires Pierre Fabre. 

“This designation underscores the urgent need for new treatment options for patients with EGFR ex20ins-mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies. It will allow us to engage more closely with the FDA to accelerate elticertinib development and bring this targeted therapy to patients faster” said Marie-Andrée Gamache, Laboratoires Pierre Fabre Pharma Chief Executive Officer.  

Contact – [email protected]

Laboratoires Pierre Fabre : FDA Fast Track designation  for elticertinib in NSCLC
Laboratoires Pierre Fabre : FDA Fast Track designation for elticertinib in NSCLC

​ 

Previous Post

Tencent Launches Hy4 flash to Power High-Speed, Cost-Efficient AI Deployment for Everyday Workflows

Next Post

AXA Partners with St James’ Settlement to Launch FutureMinds Project to Strengthen Youth Mental Resilience and Foster Healthy Digital Habits

Next Post
AXA Partners with St James’ Settlement to Launch FutureMinds Project to Strengthen Youth Mental Resilience and Foster Healthy Digital Habits

AXA Partners with St James' Settlement to Launch FutureMinds Project to Strengthen Youth Mental Resilience and Foster Healthy Digital Habits

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • MAIRE: Nextchem (MAIRE) to acquire LNG process technologies from Chart Industries for $220 million
  • Xi’an Strengthens Global Economic Ties, Expands Opportunities for Investment and Cooperation
  • Xi’an Strengthens Global Economic Ties, Expands Opportunities for Investment and Cooperation

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved